Neurol. praxi. 2018;19(1):49-52 | DOI: 10.36290/neu.2018.077

Anti CD20 multiple sclerosis therapy

doc. MUDr. Pavel Štourač, Ph.D.
Neurologická klinika FN Brno

The efficacy of multiple sclerosis therapy by monoclonal anti- CD 20 antibodies was confirmed in clinical trials. Three monoclonalantibodies ocrelizumab, rituximab and ofatumumab are effective. The efficacy of ocrelizumab was shown in relaps-remitting andprimary progressive course of multiple sclerosis and broadens the spectrum of multiple sclerosis therapy. In primary progressivecourse of multiple sclerosis ocrelizumab is the only effective therapy until now.

Keywords: CD 20, B-cells, ocrelizumab, rituximab, ofatumumab

Published: March 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štourač P. Anti CD20 multiple sclerosis therapy. Neurol. praxi. 2018;19(1):49-52. doi: 10.36290/neu.2018.077.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beauchemin P, Carruthers R. MS arising during Tocilizumab therapy for rheumatoid arthritis. Mult Scler 2016; 22(2): 254-256. Go to original source... Go to PubMed...
    2. De Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Linqvist T, Krauss W, Dring A, Bergman J, Sundstrom P, Svenningsson A. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology 2016; 87: 141-147. Go to original source... Go to PubMed...
    3. Faissner S, Nikolayczik J, Chan A, Hellwig K, Gold R, Yoon Min-Suk, Haghikia A. Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses. J Neurol 2016; 263(3): 1092-1098. Go to original source... Go to PubMed...
    4. Genain CP, Cannella B,Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 170-175. Go to original source... Go to PubMed...
    5. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL,Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 376; 3: 221-234.
    6. Kappos L, Hartung HP, Freedman MS, Boyko A, Radu EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-ontrolled, double blind, phase 2 trial. Lancet Neurol2014; 3(4): 353-363. Go to original source... Go to PubMed...
    7. Klein C, Lammens A, Schifer W,Georges G, Schwaiger M, Mossner E, Hopfner KP, Umana P, Niederfellner G. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. Mabs 2013; 5(1): 22-23. Go to original source... Go to PubMed...
    8. Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD 20 monoclonal antibodies. Arthritis Res Ther. 2013; 15(Suppl. 1): S3. Go to original source... Go to PubMed...
    9. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol 2016; 172(1): 3-13. Go to original source... Go to PubMed...
    10. Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore CS, Michel L Althekair F, Rajasekharan S, Gommerman JL, Prat A, Fillatreau S, Bar-Or A. Proinflammatory GM - CSF - producing B-cells in multiple sclerosis and B-cell depletion therapy. Sci Transl Med 2015; (7): 310 Go to original source... Go to PubMed...
    11. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovanonni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Eng J Med 2017; 376(3): 209-219. Go to original source... Go to PubMed...
    12. Mozessohn L, Chan KK, Feld JJ, Hicks LK. Hepatitis B reactivation in HBsAg - negative/HBcAb-positive patients receiving retuximab for lymphoma: a meta analysis. J Viral Hepatitis 2015; 22(10): 842-849. Go to original source... Go to PubMed...
    13. Official information about indications and usage of rituximab by FDA. Label approved on Dec 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf.
    14. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain pathol 2004; 14: 164-74. Go to original source... Go to PubMed...
    15. Sörensen PS, Lisby B,Grove R, Derosier F, Shackelford S, Havrdova E, Drulovic J, Fillipi M. Safety and efficacy of ofatumumab in relapsing remitting multiple sclerosis: a phase II study. Neurology. 2014; 82(7): 573-581. Go to original source... Go to PubMed...
    16. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody and complement - mediated demyelination. Ann Neurol 1998; (43): 465-471. Go to original source... Go to PubMed...
    17. Tony HP, Burmester G, Schulze-Koops H, Grunke M. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011; 13(3): R75. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.